Clinical trial
A Phase 2a Single-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti Viral Activity, and Pharmacokinetics of ARB-001467 in Non Cirrhotic, HBeAg Negative and Positive Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy
NCT02631096 is registered in ClinicalTrials.gov with Arbutus Biopharma Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Single-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti Viral Activity, and Pharmacokinetics of ARB-001467 in Non Cirrhotic, HBeAg Negative and Positive Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy
- Lead sponsor
- Arbutus Biopharma Corporation
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2015
- Completion date
- May 18, 2018
- Enrollment
- 36 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.